Hereditary Angioedema Market Size, Share & Forecast to 2030

The global market for Hereditary Angioedema is estimated at US$2.9 Billion in 2023 and is projected to reach US$5 Billion by 2030, growing at a CAGR of 7.7% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

Market Growth: Understand the significant growth trajectory of the C1 Esterase Inhibitors segment, which is expected to reach US$2.3 Billion by 2030 with a CAGR of a 8.2%. The Selective Bradykinin B2 Receptor Antagonists segment is also set to grow at 6.9% CAGR over the next 7 years.
Regional Analysis: Gain insights into the U.S. market, estimated at $889.5 Million in 2023, and China, forecasted to grow at an impressive 7.1% CAGR to reach $849.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

Detailed Market Analysis: Access a thorough analysis of the Global Hereditary Angioedema Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Hereditary Angioedema Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

How is the Global Hereditary Angioedema Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?

Report Features:

Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of major players such as BioCryst Pharmaceuticals, Inc., CSL Ltd., iBio, Inc., and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 46 Featured):

BioCryst Pharmaceuticals, Inc.
CSL Ltd.
iBio, Inc.
Ionis Pharmaceuticals, Inc.
Pharming Group NV
Shire PLC

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Hereditary Angioedema - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
Global Economic Update

2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Recent Past, Current & Future Analysis for Hereditary Angioedema by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 2: World Historic Review for Hereditary Angioedema by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 3: World 16-Year Perspective for Hereditary Angioedema by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
Table 4: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 5: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 6: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 7: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 8: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 9: World 16-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 10: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 11: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 12: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 13: World Recent Past, Current & Future Analysis for Hospital pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 14: World Historic Review for Hospital pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 15: World 16-Year Perspective for Hospital pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 16: World Recent Past, Current & Future Analysis for Retail pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 17: World Historic Review for Retail pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 18: World 16-Year Perspective for Retail pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 19: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 20: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 21: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 22: World Hereditary Angioedema Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
Table 23: World Recent Past, Current & Future Analysis for C1 Esterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 24: World Historic Review for C1 Esterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 25: World 16-Year Perspective for C1 Esterase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 26: World Recent Past, Current & Future Analysis for Selective Bradykinin B2 Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 27: World Historic Review for Selective Bradykinin B2 Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 28: World 16-Year Perspective for Selective Bradykinin B2 Receptor Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 29: World Recent Past, Current & Future Analysis for Kallikrein Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 30: World Historic Review for Kallikrein Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 31: World 16-Year Perspective for Kallikrein Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 32: World Recent Past, Current & Future Analysis for Subcutaneous Injections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 33: World Historic Review for Subcutaneous Injections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 34: World 16-Year Perspective for Subcutaneous Injections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES

Hereditary Angioedema Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)

CANADA

JAPAN

Hereditary Angioedema Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)

CHINA

Hereditary Angioedema Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)

EUROPE

Hereditary Angioedema Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)

FRANCE

Hereditary Angioedema Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)

GERMANY

Hereditary Angioedema Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)

ITALY

UNITED KINGDOM

Hereditary Angioedema Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)

REST OF EUROPE

ASIA-PACIFIC

Hereditary Angioedema Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)

REST OF WORLDIV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

BioCryst Pharmaceuticals, Inc.
CSL Ltd.
iBio, Inc.
Ionis Pharmaceuticals, Inc.
Pharming Group NV
Shire PLC

Table Information

Report Attribute	Details
No. of Pages	196
Published	November 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 2.9 Billion
Forecasted Market Value ( USD ) by 2030	$ 5 Billion
Compound Annual Growth Rate	7.7%
Regions Covered	Global

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4860EUR$4,950USD£4,041GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€9233EUR$9,405USD£7,679GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€14579EUR$14,850USD£12,124GBP

Hereditary Angioedema - Global Strategic Business Report

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Select Competitors (Total 46 Featured):

MarketGlass Platform

Table of Contents

Companies Mentioned (Partial List)

Table Information

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Select Competitors (Total 46 Featured):

MarketGlass Platform

Table of Contents

Companies Mentioned (Partial List)

Table Information

Related Topics

Related Reports

Urticaria and Angioedema, An Issue of Immunology and Allergy Clinics of North America. The Clinics: Internal Medicine Volume 44-3

Allergy Immunotherapy - Global Strategic Business Report

Uveitis Treatment - Global Strategic Business Report

Allergy, Inflammatory, and Autoimmune Disorders in Emergency Medicine, An Issue of Emergency Medicine Clinics of North America. The Clinics: Internal Medicine Volume 40-1

Immunology Biosimilars Market (2024 Edition): Analysis By Indication (Arthritis, Irritable Bowel Disease, Other Indications), By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)

About the Hereditary Angioedema Market